BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Theede K, Kiszka-Kanowitz M, Nordgaard-Lassen I, Mertz Nielsen A. The Impact of Endoscopic Inflammation and Mucosal Healing on Health-related Quality of Life in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:625-632. [PMID: 25956537 DOI: 10.1093/ecco-jcc/jjv081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. Qual Life Res 2018;27:273-90. [DOI: 10.1007/s11136-017-1690-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
2 Theede K, Burisch J. Defining success in treating patients with inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:645-7. [DOI: 10.1080/1744666x.2017.1317594] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J 2018;6:138-47. [PMID: 29435324 DOI: 10.1177/2050640617703842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Aniwan S, Bruining DH, Park SH, Al-Bawardy B, Kane SV, Coelho Prabhu N, Kisiel JB, Raffals LE, Papadakis KA, Pardi DS, Tremaine WJ, Loftus EV Jr. The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. J Clin Med 2019;8:E1171. [PMID: 31387259 DOI: 10.3390/jcm8081171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Shah J, Thakur ML, Dutta U. Mucosal healing in inflammatory bowel disease: Expanding horizon. Indian J Gastroenterol 2019;38:98-109. [PMID: 31037509 DOI: 10.1007/s12664-019-00950-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kiszka-Kanowitz M, Theede K, Mertz-Nielsen A. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease. Scand J Gastroenterol. 2016;51:1470-1475. [PMID: 27686002 DOI: 10.1080/00365521.2016.1216589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
7 Teich N, Grümmer H, Jörgensen E, Liceni T, Holtkamp-Endemann F, Fischer T, Hohenberger S. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months. BMC Gastroenterol 2021;21:161. [PMID: 33845784 DOI: 10.1186/s12876-021-01747-z] [Reference Citation Analysis]
8 Takano R, Osawa S, Uotani T, Tani S, Ishida N, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Miyajima H, Sugimoto K. Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission. World J Clin Cases 2018; 6(15): 952-960 [PMID: 30568951 DOI: 10.12998/wjcc.v6.i15.952] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Toyokawa Y, Takagi T, Uchiyama K, Mizushima K, Inoue K, Ushiroda C, Kashiwagi S, Nakano T, Hotta Y, Tanaka M, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Handa O, Konishi H, Naito Y, Itoh Y. Ginsenoside Rb1 promotes intestinal epithelial wound healing through extracellular signal‐regulated kinase and Rho signaling. Journal of Gastroenterology and Hepatology 2019;34:1193-200. [DOI: 10.1111/jgh.14532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
11 Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol 2020;20:18. [PMID: 31964359 DOI: 10.1186/s12876-020-1164-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
13 Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. Inflamm Bowel Dis. 2016;22:1042-1048. [PMID: 26919460 DOI: 10.1097/mib.0000000000000736] [Cited by in Crossref: 77] [Cited by in F6Publishing: 24] [Article Influence: 15.4] [Reference Citation Analysis]
14 Yarlas A, D'Haens G, Willian MK, Teynor M. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. Inflamm Bowel Dis. 2018;24:450-463. [PMID: 29361097 DOI: 10.1093/ibd/izx041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Zhang XF, Li P, Ding XL, Chen H, Wang SJ, Jin SB, Guo J, Tian ZB. Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis. Gastroenterol Rep (Oxf) 2021;9:533-42. [PMID: 34925850 DOI: 10.1093/gastro/goab026] [Reference Citation Analysis]
16 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
17 Römkens TEH, Kranenburg P, Tilburg AV, Bronkhorst C, Nagtegaal ID, Drenth JPH, Hoentjen F. Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion. J Crohns Colitis 2018;12:425-31. [PMID: 29240880 DOI: 10.1093/ecco-jcc/jjx165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
18 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Aloi M, DʼArcangelo G, Bramuzzo M, Gasparetto M, Martinelli M, Alvisi P, Illiceto MT, Valenti S, Distante M, Pellegrino S, Gatti S, Arrigo S, Civitelli F, Martelossi S; SIGENP IBD Working Group. Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1647-54. [PMID: 27271489 DOI: 10.1097/MIB.0000000000000828] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
20 Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016;11:e0165435. [PMID: 27776175 DOI: 10.1371/journal.pone.0165435] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 9.7] [Reference Citation Analysis]
21 Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res 2018;16:522-8. [PMID: 30321913 DOI: 10.5217/ir.2018.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. Dig Dis Sci 2016;61:1692-9. [PMID: 26743764 DOI: 10.1007/s10620-015-4013-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
23 Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J. 2018;6:138-147. [PMID: 29435324 DOI: 10.1177/2050640617703842,] [Cited by in F6Publishing: 1] [Reference Citation Analysis]